Dorothea Fischer
Overview
Explore the profile of Dorothea Fischer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt M, Hesse T, Hoffmann O, Heinrich B, Park-Simon T, Grischke E, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941823
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced...
2.
Laferton J, Schiller S, Conrad D, Fischer D, Zimmermann-Viehoff F
Stress Health
. 2024 Apr;
40(4):e3410.
PMID: 38642346
Health care workers are at increased risk for mental health issues due to high psychological and physical job demands. According to a recent study, stress beliefs (i.e., believing stress to...
3.
Schliemann A, Teroerde A, Beurer B, Hammersen F, Fischer D, Katalinic A, et al.
Curr Oncol
. 2023 Dec;
30(12):10057-10074.
PMID: 38132365
Background: Approximately 27% of female breast cancer patients are diagnosed before the age of 55, a group often comprising mothers with young children. Maternal psychosocial well-being significantly impacts these children's...
4.
Luck H, Schmidt M, Hesse T, Hoffmann O, Heinrich B, Park-Simon T, et al.
Oncologist
. 2023 Aug;
28(12):e1152-e1159.
PMID: 37555463
Background: Eribulin, a halichondrin-class microtubule dynamics inhibitor, is a preferred treatment option for patients with advanced breast cancer who have been pretreated with an anthracycline and a taxane. Peripheral neuropathy...
5.
Chu C, Schonbrunn A, Fischer D, Liu Y, Hocher J, Weinerth J, et al.
Front Immunol
. 2023 Jun;
14:1187880.
PMID: 37377957
Due to rare but major adverse reactions to the AstraZeneca adenoviral ChAdOx1-S-nCoV-19 vaccine (ChAd), German health authorities recommended adults under 60 who received one dose of ChAd, to receive a...
6.
Hammersen F, Fischer D, Pursche T, Strobel A, Katalinic A, Labohm L, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980656
A known cut-off problem hampers the interpretation of quality of life (QOL) scores. The purpose of this study was to apply a novel approach for the EORTC QLQ-C30 instrument to...
7.
Beurer B, Sprenger L, Graness K, Feldmann F, Warnke U, Biersack M, et al.
J Oncol Pharm Pract
. 2022 Sep;
29(4):967-970.
PMID: 36128835
Introduction: PARP (Poly ADP Ribose Polymerase) inhibitors are an effective maintenance therapy for various entities, such as BRCA (breast cancer gene) mutated or HRD (homologous recombination deficiency) positive primary platin-sensitive...
8.
Pruessmann J, Pursche T, Hammersen F, Katalinic A, Fischer D, Waldmann A
Breast Care (Basel)
. 2021 May;
16(2):163-172.
PMID: 34012371
Background: Breast cancer in young women is associated with unfavourable tumour biology and is the main cause of death in this group. Conditional survival analysis estimates survival rates under the...
9.
Hemmati P, Fischer D, Breywisch F, Wohlfarth S, Kramer M, Paland M, et al.
Oncol Res Treat
. 2021 May;
44(6):354-359.
PMID: 33940575
Treatment of cancer patients has become challenging when large parts of hospital services need to be shut down as a consequence of a local COVID-19 outbreak that requires rapid containment...
10.
Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A
Psychooncology
. 2020 Nov;
30(3):361-368.
PMID: 33137218
Objective: To evaluate the psychosocial situation of breast cancer (BC) patients with dependent children, with regard to who used family-centered psychosocial support (PS) services, reasons against using it, as well...